ProteoDesign, a biotech spin-out from Princeton University and University of Barcelona and member of CataloniaBio & HealthTech, has raised a financing round of 1.7 million euros led by existing investor Caixa Capital Risc and joined by an undisclosed private investor.

The company is developing personalized immunological treatments against cancer through patented technology discovered after more than 20 years of pioneering research in this field. The funds obtained will be used to advance candidates for drugs in the preclinical phase.

Dr. Miquel Vila Perelló, CEO of ProteoDesign, explained in this interview by CataloniaBio & HealthTech that "the conjugated antibodies are a class of new promising biotherapeutic agents in oncology". Their great advantage over traditional chemotherapeutic approaches, "is they allow the selective elimination of cancer cells, without affecting healthy cells, thus reducing the risk of side effects and providing a window wider therapeutic".

The facilities of the company are located at the Barcelona Science Park (PCB).

Photo: Miquel Vila Perelló is co-Founder and CEO of the company - © ProteoDesign